Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.
Market Dynamics
Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches is supporting the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by industry players are expected to boost global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.
Key features of the study:
This report provides in-depth analysis of global chronic obstructive pulmonary disease (COPD) treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market
Detailed Segmentation:
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
Oral
Inhalation
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
North America
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Bronchodilators
Beta 2-Agonists
Anticholinergics
Theophyllines
Phosphodiesterase Type 4 Inhibitors
Steroids
Others
By Route of Administration:
Oral
Inhalation
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
AstraZeneca Plc*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Orion Corporation
Mylan N.V.
Boehringer Ingelheim
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Novartis AG
Sunovion Pharmaceuticals, Inc.
CHIESI Farmaceutici SpA
“*” marked represents similar segmentation in other categories in the respective section.